Our observation that individuals suffering from recognised severe COVID-19 comorbidities may have lower pre-infection ACE2 levels in some tissues may support the theory that low ACE2 levels in at risk-individuals are then reduced further upon SARS-CoV-2 infection, contributing to the dysregulation of the RAS characteristic of severe COVID-1944. The gene discussed is ACE2; the disease is COVID-19.